>中东和非洲共济失调市场,按类型(脊髓小脑共济失调、共济失调-毛细血管扩张症、发作性共济失调和其他(多系统萎缩 (MSA)))、产品(治疗和诊断)、剂型(固体、液体和其他)、给药途径(口服、肠胃外和其他)、患者类型(成人、儿童和老年人)、最终用户(医院、诊所、家庭医疗保健和其他)、分销渠道(直接招标、零售销售和其他)划分 - 行业趋势和预测到 2029 年。
中东和非洲共济失调市场分析和见解
共济失调症的日益流行增加了市场的需求。为获得更好的医疗服务而增加的医疗支出也促进了市场的增长。在这个关键时期,主要市场参与者高度关注产品发布和产品审批。此外,由于新兴市场的激增,政府和监管机构正在通过产品审批来支持市场参与者。
由于市场参与者的增加和先进产品的供应,预测年中东和非洲共济失调市场将增长。与此同时,制造商正致力于研发活动,以向市场推出新产品。共济失调治疗领域的研究不断增加,酒精和药物消费量增加,预计将进一步推动市场增长。然而,在预测期内,诊断疾病的困难和一些发展中国家缺乏基因检测设施可能会阻碍中东和非洲共济失调市场的增长。
医疗支出的增加和市场参与者的战略举措可能为市场提供改善治疗的机会。然而,与药品和产品审批以及各公司产品召回相关的一些严格规则和法规预计将对市场增长构成挑战。
预计中东和非洲共济失调市场将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析称,在 2022 年至 2029 年的预测期内,该市场将以 4.6% 的复合年增长率增长,预计将从 2021 年的 37.738 万美元达到 2029 年的 51.838 万美元。
报告指标 |
细节 |
预测期 |
2022 至 2029 年 |
基准年 |
2021 |
历史岁月 |
2020 |
定量单位 |
收入(千美元),定价(美元) |
涵盖的领域 |
By Type (Spinocerebellar Ataxias, Ataxia-Telangiectasia, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), Product (Treatment and Diagnosis), Dosage Form (Solid, Liquids, and Others), Route of Administration (Oral, Parenteral, and Others), Patient Type (Adult, Child, and Geriatric), End User (Hospital, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) |
Countries Covered |
South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait, the Rest of the Middle East and Africa |
Market Players Covered |
Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Cipla Inc., among others |
Market Definition
Ataxia is a term for a group of disorders that affect coordination, balance, and speech. Anybody part can be affected, but people with ataxia often have difficulties with balance, walking, speaking, swallowing, and tasks requiring a high degree of control, such as writing, eating, and vision. The exact symptoms and their severity vary depending on the type of ataxia a person has.
Ataxia usually results from damage to a part of the brain called the cerebellum, but it can also be caused by damage to other parts of the nervous system. This damage can be part of an underlying condition such as MS (multiple sclerosis) or can be caused by a head injury, lack of oxygen to the brain, or long-term, excessive alcohol consumption. Hereditary ataxia is caused by a faulty gene passed on by family members who may or may not be affected.
Middle East and Africa Ataxia Market Dynamics
Drivers
- Rapid research in the field of ataxia therapeutics
There is an enormous range of risk factors being reported for ataxia. Hence, to reduce the risk factors and symptoms associated with it, various research is going on in ataxia treatments. Some government funding has also been initiated to treat various types of ataxia in the market. Various rapid research in the field of ataxia therapeutics may help drive the market over the forecasted period and anticipate the major growth in the research and development for the same.
- Rise in alcohol and drug usage
Rising alcohol and drug usage can lead to vitamin B-12, vitamin E, and thiamine deficiency. The lack of these nutrients in the body is considered to be a major cause of ataxia. A shortage of vitamin E in the body can lead to neurological problems, such as difficulty coordinating movements (ataxia) and speech (dysarthria), loss of reflexes in the legs (lower limb areflexia), and a loss of sensation in the extremities (peripheral neuropathy) this then leads to the various types ataxia. The rising number of people and youth consuming excessive alcohol and drugs also increases the chance of being affected by various types of ataxia. This is expected to act as a driver for the growth of the Middle East and Africa ataxia market.
Opportunities
- Rising healthcare expenditure
Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, the government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities for ataxia as the disorder has been highly prevalent in recent years.
Also, the strategic initiatives taken by key market players will provide structural integrity and future opportunities for the ataxia market in the forecast period of 2022-2029.
Restraints/Challenges
However, the difficulty in diagnosing the disease and lack of genetic testing facilities in some developing countries will impede the growth rate of the Middle East and Africa ataxia market. Additionally, stringent rules and regulations will further challenge the forecast period's market.
This Middle East and Africa ataxia market report provide details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa ataxia market, contact Data Bridge Market Research for an Analyst Brief; our team will help you make an informed market decision to achieve market growth.
Post COVID-19 Impact on Middle East and Africa Ataxia Market
COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence, various treatment drugs have widely increased in the world's population. Thus, the pandemic has positively affected this market.
Recent Development
- In November 2021, Sanofi announced that the company had completed its acquisition with Kadmon. This has helped the company expand its product portfolio and increase its revenue through various generic medicine products
Middle East and Africa Market Scope
The Middle East and Africa ataxia market is segmented into type, product, dosage form, route of administration, patient type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Type
- Spinocerebellar Ataxias
- Ataxia-Telangiectasia
- Episodic Ataxia
- Others (Multiple System Atrophy (MSA))
根据类型,中东和非洲共济失调市场分为脊髓小脑性共济失调、毛细血管扩张性共济失调、发作性共济失调和其他(多系统萎缩 (MSA))。
产品
- 诊断
- 治疗
根据产品,中东和非洲共济失调市场分为治疗和诊断。
剂型
- 坚硬的
- 液体
- 其他的
根据剂型,中东和非洲共济失调市场分为固体、液体和其他。
.给药途径
- 口服
- 肠外
- 其他的
根据给药途径,中东和非洲共济失调市场分为口服、肠外和其他。
患者类型
- 成人
- 孩子
- 老年
根据患者类型,中东和非洲共济失调市场分为成人、儿童和老年人。
最终用户
- 医院
- 诊所
- 家庭医疗保健
- 其他的
根据最终用户,中东和非洲共济失调市场分为医院、诊所、家庭医疗保健和其他。
分销渠道
- 直接招标
- 零售销售
- 其他的
根据分销渠道,中东和非洲共济失调市场分为直接招标、零售销售和其他。
中东和非洲 共济失调市场区域分析/见解
对中东和非洲共济失调市场进行了分析,并按国家、类型、产品、剂型、给药途径、患者类型、最终用户和分销渠道提供了市场规模洞察和趋势。
该地区涵盖的国家包括南非、沙特阿拉伯、阿联酋、埃及、以色列、科威特、中东和非洲其他地区。南非预计将在市场份额和收入方面主导中东和非洲共济失调市场,并将在预测期内继续保持主导地位。这是由于该地区共济失调患病率高,快速的研究发展正在推动市场发展。
报告的国家部分还提供了影响单个市场因素和市场法规变化的信息,这些因素和变化会影响市场的当前和未来趋势。新旧销售、国家人口统计、疾病流行病学和进出口关税等数据点是预测单个国家市场情况的一些主要指标。此外,在对国家数据进行预测分析时,还考虑了中东和非洲品牌的存在和可用性以及它们因本土和国内品牌的激烈竞争而面临的挑战以及销售渠道的影响。
竞争格局和中东和非洲共济失调 市场份额分析
中东和非洲共济失调市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对中东和非洲共济失调市场的关注有关。
中东和非洲共济失调市场的一些主要参与者包括诺华公司、默克公司、阿拉宾度制药公司、辉瑞公司、赛诺菲、梯瓦制药工业有限公司、Viatris 公司、太阳制药工业有限公司、Lupin 公司、西普拉公司等。
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析以及主要(行业专家)验证。除此之外,数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、中东和非洲与地区以及供应商份额分析。如有进一步询问,请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA ATAXIA MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
4.3 EPIDEMIOLOGY
5 PIPELINE ANALYSIS
6 MIDDLE EAST & AFRICA ATAXIA MARKET: REGULATORY SCENARIO
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE AND INCIDENCES OF ATAXIA
7.1.2 RAPID RESEARCH IN FIELD OF ATAXIA THERAPEUTICS
7.1.3 RISE IN ALCOHOL AND DRUG USAGE
7.1.4 GROWING NUMBER OF INCIDENCES OF AUTO-IMMUNE DISEASE
7.2 RESTRAINTS
7.2.1 DIFFICULTY IN DIAGNOSIS OF DISEASE
7.2.2 LACK OF GENETIC TESTING IN DEVELOPING COUNTRIES
7.3 OPPORTUNITIES
7.3.1 RISING HEALTHCARE EXPENDITURE
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.4 CHALLENGES
7.4.1 STRINGENT RULES AND REGULATIONS
7.4.2 PRODUCT RECALL
8 MIDDLE EAST & AFRICA ATAXIA MARKET, BY TYPE
8.1 OVERVIEW
8.2 SPINOCEREBELLAR ATAXIAS
8.2.1 TYPE 3
8.2.2 TYPE 2
8.2.3 TYPE 1
8.2.4 OTHERS
8.3 ATAXIA-TELANGIECTASIA
8.4 EPISODIC ATAXIA
8.5 OTHERS (MULTIPLE SYSTEM ATROPHY (MSA))
9 MIDDLE EAST & AFRICA ATAXIA MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 TREATMENT
9.2.1 PHARMACOTHERAPY
9.2.1.1 STIFFNESS/SPASTICITY
9.2.1.1.1 GABAPENTIN
9.2.1.1.2 LEVODOPA
9.2.1.1.3 OTHERS
9.2.1.2 GAIT AND TREMORS
9.2.1.2.1 VARENICLINE
9.2.1.2.2 RILUZOLE
9.2.1.2.3 AMANTADINE
9.2.1.2.4 OTHERS
9.2.1.3 ANTI-OXIDANTS
9.2.1.3.1 N‐ACETYLCYSTEINE
9.2.1.3.2 SELEGILINE
9.2.1.3.3 DEHYDROEPIANDROSTERONE
9.2.1.3.4 VITAMIN E
9.2.1.4 NON ANTI-OXIDANTS
9.2.1.4.1 ERYTHROPOIETIN
9.2.1.4.2 DEFERIPRONE
9.2.1.4.3 RESVERATROL
9.2.1.4.4 HISTONE DEACETYLASE INHIBITORS
9.2.1.5 ANTI-ARRHYTHMIC AGENTS
9.2.1.5.1 AMIODARONE
9.2.1.5.2 PROPAFENONE
9.2.1.5.3 FLECAINIDE
9.2.1.5.4 IBUTILIDE
9.2.1.6 ANTI-CARDIAC FAILURE
9.2.1.6.1 BENAZEPRIL
9.2.1.6.2 LISINOPRIL
9.2.1.6.3 CAPTOPRIL
9.2.1.6.4 ENALAPRIL
9.2.1.6.5 FOSINOPRIL
9.2.1.6.6 MOEXIPRIL
9.2.1.6.7 OTHERS
9.2.1.7 ORAL HYPOGLYCEMIC THERAPEUTICS
9.2.1.7.1 BIGUANIDES (METFORMIN)
9.2.1.7.2 SULFONYLUREAS
9.2.1.7.2.1 GLIPIZIDE
9.2.1.7.2.2 GLIMEPIRIDE
9.2.1.7.2.3 GLYBURIDE
9.2.1.7.2.4 OTHERS
9.2.1.7.3 THIAZOLIDINEDIONES
9.2.1.7.4 MEGLITINIDES
9.2.2 LIFESTYLE THERAPY
9.2.2.1 PHYSICAL THERAPY
9.2.2.2 SPEECH THERAPY
9.2.2.3 PALLIATIVE CARE
9.2.2.4 OTHERS
9.2.3 SUPPORTIVE DEVICES
9.2.3.1 WALKING AIDS
9.2.3.2 WHEELCHAIRS
9.2.3.3 OTHERS
9.3 DIAGNOSTICS
9.3.1 IMAGING TEST
9.3.1.1 MRI SCAN
9.3.1.2 OTHERS
9.3.2 BLOOD TEST
9.3.3 GENETIC TESTING
10 MIDDLE EAST & AFRICA ATAXIA MARKET, BY DOSAGE FORM
10.1 OVERVIEW
10.2 SOLID
10.2.1 TABLETS
10.2.2 CAPSULES
10.2.3 OTHERS
10.3 LIQUIDS
10.3.1 INJECTION
10.3.2 SOLUTIONS
10.3.3 OTHERS
10.4 OTHERS
11 MIDDLE EAST & AFRICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.3 PARENTERAL
11.4 OTHERS
12 MIDDLE EAST & AFRICA ATAXIA MARKET, BY PATIENT TYPE
12.1 OVERVIEW
12.2 ADULT
12.2.1 MALE
12.2.2 FEMALE
12.3 CHILD
12.4 GERIATRIC
13 MIDDLE EAST & AFRICA ATAXIA MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 MIDDLE EAST & AFRICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 RETAIL SALES
14.3.1 HOSPITAL PHARMACY
14.3.2 RETAIL SHOP
14.3.3 ONLINE PHARMACY
14.4 OTHERS
15 MIDDLE EAST & AFRICA ATAXIA MARKET, BY GEOGRAPHY
15.1 MIDDLE EAST AND AFRICA
15.1.1 SOUTH AFRICA
15.1.2 SAUDI ARABIA
15.1.3 U.A.E
15.1.4 ISRAEL
15.1.5 EGYPT
15.1.6 KUWAIT
15.1.7 REST OF MIDDLE EAST AND AFRICA
16 MIDDLE EAST & AFRICA ATAXIA MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 SELECT MEDICAL CORPORATION
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 PFIZER INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 NOVARTIS AG
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 AMNEAL PHARMACEUTICALS LLC.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLI
18.4.5 RECENT DEVELOPMENT
18.5 UPSTREAM REHABILITATION INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 COMPANY SHARE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 PRIORY
18.6.1 COMPANY SNAPSHOT
18.6.2 COMPANY SHARE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 ACORDA THERAPEUTICS, INC.
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 ADVERUM BIOTECHNOLOGIES, INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 APOTEX INC.
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENT
18.1 ATI PHYSICAL THERAPY
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 AUROBINDO PHARMA
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENT
18.12 BANNER HEALTH
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 BIOHAVEN PHARMACEUTICALS
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 BIOVISTA
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 CIPLA INC.
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENT
18.16 DESIGN THERAPEUTICS, INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENT
18.17 INTRABIO
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENT
18.18 LUPIN.
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENTS
18.19 MATRIX BIOMED
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENT
18.2 MERCK KGAA
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENTS
18.21 REATA PHARMACEUTICALS, INC.
18.21.1 COMPANY SNAPSHOT
18.21.2 PRODUCT PORTFOLIO
18.21.3 RECENT DEVELOPMENT
18.22 RETROTOPE INC.
18.22.1 COMPANY SNAPSHOT
18.22.2 PRODUCT PORTFOLIO
18.22.3 RECENT DEVELOPMENT
18.23 SANOFI
18.23.1 COMPANY SNAPSHOT
18.23.2 REVENUE ANALYSIS
18.23.3 PRODUCT PORTFOLIO
18.23.4 RECENT DEVELOPMENT
18.24 SUN PHARMACEUTICAL INDUSTRIES LTD.
18.24.1 COMPANY SNAPSHOT
18.24.2 REVENUE ANALYSIS
18.24.3 PRODUCT PORTFOLIO
18.24.4 RECENT DEVELOPMENT
18.25 SUTTER HEALTH
18.25.1 COMPANY SNAPSHOT
18.25.2 PRODUCT PORTFOLIO
18.25.3 RECENT DEVELOPMENTS
18.26 TEVA PHARMACEUTICAL INDUSTRIES LTD.
18.26.1 COMPANY SNAPSHOT
18.26.2 REVENUE ANALYSIS
18.26.3 PRODUCT PORTFOLIO
18.26.4 RECENT DEVELOPMENT
18.27 VIATRIS INC.
18.27.1 COMPANY SNAPSHOT
18.27.2 REVENUE ANALYSIS
18.27.3 PRODUCT PORTFOLIO
18.27.4 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
表格列表
TABLE 1 MIDDLE EAST & AFRICA ATAXIA MARKET: PIPELINE ANALYSIS
TABLE 2 MIDDLE EAST & AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 3 MIDDLE EAST & AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 4 MIDDLE EAST & AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 5 MIDDLE EAST & AFRICA ATAXIA-TELANGIECTASIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 6 MIDDLE EAST & AFRICA EPISODIC ATAXIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 7 MIDDLE EAST & AFRICA OTHERS (MULTIPLE SYSTEM ATROPHY (MSA)) IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 8 MIDDLE EAST & AFRICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 9 MIDDLE EAST & AFRICA TREATMENT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 10 MIDDLE EAST & AFRICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 11 MIDDLE EAST & AFRICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 12 MIDDLE EAST & AFRICA STIFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 13 MIDDLE EAST & AFRICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 14 MIDDLE EAST & AFRICA ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 15 MIDDLE EAST & AFRICA NON ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 16 MIDDLE EAST & AFRICA ANTI- ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 17 MIDDLE EAST & AFRICA ANTI- CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 18 MIDDLE EAST & AFRICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 19 MIDDLE EAST & AFRICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 20 MIDDLE EAST & AFRICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 21 MIDDLE EAST & AFRICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 22 MIDDLE EAST & AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 23 MIDDLE EAST & AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 24 MIDDLE EAST & AFRICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 25 MIDDLE EAST & AFRICA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 26 MIDDLE EAST & AFRICA SOLID IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 27 MIDDLE EAST & AFRICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 28 MIDDLE EAST & AFRICA LIQUIDS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 29 MIDDLE EAST & AFRICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 30 MIDDLE EAST & AFRICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 31 MIDDLE EAST & AFRICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 32 MIDDLE EAST & AFRICA ORAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 33 MIDDLE EAST & AFRICA PARENTERAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 34 MIDDLE EAST & AFRICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 35 MIDDLE EAST & AFRICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 36 MIDDLE EAST & AFRICA ADULT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 37 MIDDLE EAST & AFRICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 38 MIDDLE EAST & AFRICA CHILD IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 39 MIDDLE EAST & AFRICA GERIATRIC IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 40 MIDDLE EAST & AFRICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 41 MIDDLE EAST & AFRICA HOSPITAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 42 MIDDLE EAST & AFRICA CLINICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 43 MIDDLE EAST & AFRICA HOME HEALTHCARE IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 44 MIDDLE EAST & AFRICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 45 MIDDLE EAST & AFRICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 46 MIDDLE EAST & AFRICA DIRECT TENDER IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 47 MIDDLE EAST & AFRICA RETAIL SALES IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 48 MIDDLE EAST & AFRICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 49 MIDDLE EAST & AFRICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 59 MIDDLE EAST AND AFRICA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 61 MIDDLE EAST AND AFRICA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 62 MIDDLE EAST AND AFRICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 63 MIDDLE EAST AND AFRICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 64 MIDDLE EAST AND AFRICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 65 MIDDLE EAST AND AFRICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 66 MIDDLE EAST AND AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 67 MIDDLE EAST AND AFRICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 68 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 69 MIDDLE EAST AND AFRICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 70 MIDDLE EAST AND AFRICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 71 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 72 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 73 MIDDLE EAST AND AFRICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 74 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 75 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 76 MIDDLE EAST AND AFRICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 77 SOUTH AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 78 SOUTH AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 79 SOUTH AFRICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 80 SOUTH AFRICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 81 SOUTH AFRICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 82 SOUTH AFRICA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 83 SOUTH AFRICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 84 SOUTH AFRICA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 85 SOUTH AFRICA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 86 SOUTH AFRICA ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 87 SOUTH AFRICA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 88 SOUTH AFRICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 89 SOUTH AFRICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 90 SOUTH AFRICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 91 SOUTH AFRICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 92 SOUTH AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 93 SOUTH AFRICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 94 SOUTH AFRICA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 95 SOUTH AFRICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 96 SOUTH AFRICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 97 SOUTH AFRICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 98 SOUTH AFRICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 99 SOUTH AFRICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 100 SOUTH AFRICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 101 SOUTH AFRICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 102 SOUTH AFRICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 103 SAUDI ARABIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 104 SAUDI ARABIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 105 SAUDI ARABIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 106 SAUDI ARABIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 107 SAUDI ARABIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 108 SAUDI ARABIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 109 SAUDI ARABIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 110 SAUDI ARABIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 111 SAUDI ARABIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 112 SAUDI ARABIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 113 SAUDI ARABIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 114 SAUDI ARABIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 115 SAUDI ARABIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 116 SAUDI ARABIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 117 SAUDI ARABIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 118 SAUDI ARABIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 119 SAUDI ARABIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 120 SAUDI ARABIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 121 SAUDI ARABIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 122 SAUDI ARABIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 123 SAUDI ARABIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 124 SAUDI ARABIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 125 SAUDI ARABIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 126 SAUDI ARABIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 127 SAUDI ARABIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 128 SAUDI ARABIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 129 U.A.E ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 130 U.A.E SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 131 U.A.E ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 132 U.A.E TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 133 U.A.E PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 134 U.A.E STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 135 U.A.E GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 136 U.A.E ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 137 U.A.E NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 138 U.A.E ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 139 U.A.E ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 140 U.A.E ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 141 U.A.E SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 142 U.A.E LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 143 U.A.E SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 144 U.A.E DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 145 U.A.E IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 146 U.A.E IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 147 U.A.E SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 148 U.A.E LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 149 U.A.E ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 150 U.A.E ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 151 U.A.E ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 152 U.A.E ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 153 U.A.E ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 154 U.A.E RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 155 ISRAEL ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 156 ISRAEL SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 157 ISRAEL ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 158 ISRAEL TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 159 ISRAEL PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 160 ISRAEL STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 161 ISRAEL GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 162 ISRAEL ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 163 ISRAEL NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 164 ISRAEL ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 165 ISRAEL ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 166 ISRAEL ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 167 ISRAEL SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 168 ISRAEL LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 169 ISRAEL SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 170 ISRAEL DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 171 ISRAEL IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 172 ISRAEL IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 173 ISRAEL SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 174 ISRAEL LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 175 ISRAEL ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 176 ISRAEL ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 177 ISRAEL ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 178 ISRAEL ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 179 ISRAEL ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 180 ISRAEL RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 181 EGYPT ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 182 EGYPT SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 183 EGYPT ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 184 EGYPT TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 185 EGYPT PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 186 EGYPT STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 187 EGYPT GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 188 EGYPT ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 189 EGYPT NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 190 EGYPT ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 191 EGYPT ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 192 EGYPT ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 193 EGYPT SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 194 EGYPT LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 195 EGYPT SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 196 EGYPT DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 197 EGYPT IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 198 EGYPT IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 199 EGYPT SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 200 EGYPT LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 201 EGYPT ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 202 EGYPT ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 203 EGYPT ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 204 EGYPT ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 205 EGYPT ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 206 EGYPT RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 207 KUWAIT ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 208 KUWAIT SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 209 KUWAIT ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 210 KUWAIT TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 211 KUWAIT PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 212 KUWAIT STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 213 KUWAIT GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 214 KUWAIT ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 215 KUWAIT NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 216 KUWAIT ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 217 KUWAIT ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 218 KUWAIT ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 219 KUWAIT SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 220 KUWAIT LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 221 KUWAIT SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 222 KUWAIT DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 223 KUWAIT IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 224 KUWAIT IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 225 KUWAIT SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 226 KUWAIT LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 227 KUWAIT ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 228 KUWAIT ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 229 KUWAIT ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 230 KUWAIT ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 231 KUWAIT ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 232 KUWAIT RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 233 REST OF MIDDLE EAST AND AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
图片列表
FIGURE 1 MIDDLE EAST & AFRICA ATAXIA MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA ATAXIA MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA ATAXIA MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA ATAXIA MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA ATAXIA MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA ATAXIA MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA ATAXIA MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA ATAXIA MARKET: END USER COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA ATAXIA MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA ATAXIA MARKET: SEGMENTATION
FIGURE 11 RAPID RESEARCH IN FIELD OF ATAXIA THEREPEUTICS IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA ATAXIA MARKET IN THE FORECAST PERIOD
FIGURE 12 SPINOCEREBELLAR ATAXIAS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA ATAXIA MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA ATAXIA MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA ATAXIA MARKET
FIGURE 15 MIDDLE EAST & AFRICA ATAXIA MARKET: BY TYPE, 2021
FIGURE 16 MIDDLE EAST & AFRICA ATAXIA MARKET: BY TYPE, 2022-2029 (USD THOUSAND)
FIGURE 17 MIDDLE EAST & AFRICA ATAXIA MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 18 MIDDLE EAST & AFRICA ATAXIA MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PRODUCT, 2021
FIGURE 20 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PRODUCT, 2022-2029 (USD THOUSAND)
FIGURE 21 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 22 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 23 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DOSAGE FORM, 2021
FIGURE 24 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DOSAGE FORM, 2022-2029 (USD THOUSAND)
FIGURE 25 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 26 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 27 MIDDLE EAST & AFRICA ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 28 MIDDLE EAST & AFRICA ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD THOUSAND)
FIGURE 29 MIDDLE EAST & AFRICA ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 30 MIDDLE EAST & AFRICA ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 31 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PATIENT TYPE, 2021
FIGURE 32 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PATIENT TYPE, 2022-2029 (USD THOUSAND)
FIGURE 33 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 34 MIDDLE EAST & AFRICA ATAXIA MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA ATAXIA MARKET: BY END USER, 2021
FIGURE 36 MIDDLE EAST & AFRICA ATAXIA MARKET: BY END USER, 2022-2029 (USD THOUSAND)
FIGURE 37 MIDDLE EAST & AFRICA ATAXIA MARKET: BY END USER, CAGR (2022-2029)
FIGURE 38 MIDDLE EAST & AFRICA ATAXIA MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 40 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)
FIGURE 41 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 42 MIDDLE EAST & AFRICA ATAXIA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA ATAXIA MARKET: SNAPSHOT (2021)
FIGURE 44 MIDDLE EAST AND AFRICA ATAXIA MARKET: BY COUNTRY (2021)
FIGURE 45 MIDDLE EAST AND AFRICA ATAXIA MARKET: BY COUNTRY (2022 & 2029)
FIGURE 46 MIDDLE EAST AND AFRICA ATAXIA MARKET: BY COUNTRY (2021 & 2029)
FIGURE 47 MIDDLE EAST AND AFRICA ATAXIA MARKET: BY TYPE (2022-2029)
FIGURE 48 MIDDLE EAST & AFRICA ATAXIA MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.